Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0K0IM
|
|||
Former ID |
DIB014873
|
|||
Drug Name |
MK-8666
|
|||
Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
Company |
Merck
|
|||
Structure |
Download2D MOL |
|||
Formula |
C29H31NO6S
|
|||
Canonical SMILES |
CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=NC=C4C5C(C5C(=O)O)CC4=C3)C)OCCCS(=O)(=O)C
|
|||
InChI |
1S/C29H31NO6S/c1-17-10-22(35-8-5-9-37(3,33)34)11-18(2)26(17)20-7-4-6-19(12-20)16-36-25-14-21-13-23-27(24(21)15-30-25)28(23)29(31)32/h4,6-7,10-12,14-15,23,27-28H,5,8-9,13,16H2,1-3H3,(H,31,32)/t23-,27-,28+/m1/s1
|
|||
InChIKey |
CODQKEMYZZKQAE-QPVYNBJUSA-N
|
|||
CAS Number |
CAS 1544739-75-4
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01971554) Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003). U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.